Medimaps Group S.A. announced that it has entered into a strategic merger agreement with Radiobotics ApS, bringing together two specialized artificial intelligence medical imaging companies to create a global provider of AI-driven musculoskeletal imaging software.
The deal, which is subject to Danish foreign direct investment approval and other customary closing conditions, is designed to accelerate adoption of AI-enabled MSK imaging across both preventative bone health and acute trauma diagnostics.
The combined organization will offer a comprehensive portfolio spanning X-ray and DXA modalities, including automated fracture detection, opportunistic bone fragility assessment, and fracture risk prediction. Medimaps’ bone microarchitecture solutions, including TBS Osteo and TBS Reveal, will be integrated with Radiobotics’ RBfracture platform, which detects trauma-related findings such as fractures and dislocations. These tools are designed to integrate directly into radiology workflows through PACS-enabled capabilities.
By unifying complementary technologies, clinical validation, and global commercial networks, the merged entity aims to establish what it describes as the first end-to-end MSK AI ecosystem. The company plans to leverage its combined expertise and distribution channels to reach hospitals, clinics, and imaging centers across 90 countries, including the United States. Both organizations will retain their established brands while collaborating closely on research and development and commercial initiatives.
The merger addresses growing clinical and economic pressures tied to fractures and osteoporosis. Fractures remain among the most common and operationally demanding challenges in emergency and hospital settings, where high trauma volumes and time-sensitive decision-making increase the risk of missed or delayed diagnoses. Osteoporosis-related fragility fractures alone are estimated to cost healthcare systems $22 billion annually, with projections exceeding $95 billion by 2040. The companies believe that AI-enabled imaging can improve the speed and consistency of fracture assessment while enabling earlier identification of bone fragility and more accurate fracture risk prediction.
A combined executive team will lead the new organization, maintaining leadership continuity from both companies while fostering a collaborative growth strategy. Financial terms of the transaction were not disclosed.
KEY QUOTES:
“This merger represents a pivotal milestone in Medimaps Group’s long-term strategy to strengthen our leadership in bone health assessment. Our ambition is to give radiologists a single, trusted platform that brings together fracture detection and fracture risk prediction across the continuum of care, so clinicians can make better decisions, patients receive better outcomes, and healthcare systems benefit from more efficient, evidence-based care.”
Univ.-Prof. Dr. Didier Hans, Co-founder and CEO, Medimaps Group
“Radiobotics has always been driven by scientific rigor and real-world clinical impact. Joining Medimaps Group will accelerate access to our technology. It’s an important step in our vision to ensure patients receive immediate and precise, expert-level care in MSK imaging, 24/7, regardless of time, infrastructure, or staffing constraints.”
Peter Ulvskjold, CEO, Radiobotics and Member of the Medimaps Group Executive Committee
